Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta
Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta
复制标题
DOI：
10.1016/j.bone.2004.03.008
复制
发表时间：
2004-07-01
期刊：
影响因子：
4.1
通讯作者：
Glorieux, FH
中科院分区：
文献类型：
--
作者：
Munns, CF;Rauch, F;Glorieux, FH
本报告旨在描述4例小于2岁的严重成骨不全症婴儿（01）与第一个帕米膦酸钠周期相关的不良呼吸事件。在一项观察试验中，59例重症01患儿开始周期性静脉注射帕米膦酸盐治疗。在每个输注周期中进行常规观察。在第一个治疗周期，4名（7%）先前存在呼吸损害的婴儿出现呼吸窘迫。呼吸窘迫经支气管扩张剂治疗成功。其中两名婴儿需要重症监护。在随后的帕米膦酸钠输注周期中没有呼吸窘迫的复发。对于严重成骨不全且既往存在呼吸损害的婴儿，第一次帕米膦酸钠输注周期可能与呼吸功能急性恶化有关。病因尚不清楚，但可能涉及细胞因子释放和/或在第一个输注周期内液体给药引起的血流动力学损害。在整个第一个治疗周期密切监测是至关重要的。(C) 2004爱思唯尔公司版权所有。
This report aims to describe the adverse respiratory events associated with the first pamidronate cycle in four infants with severe osteogenesis imperfecta (01) who were less than 2 years of age.Fifty-nine infants with severe 01 were commenced on cyclical intravenous pamidronate therapy in an observation trial. Routine observations were measured during each infusion cycle.During the first treatment cycle, four infants (7%) with preexisting respiratory compromise developed respiratory distress. The respiratory distress was successfully managed with bronchodilator therapy. Two of the infants required intensive care admission. There was no recurrence of respiraton, distress with subsequent pamidronate infusion cycles.In infants with severe OI and preexisting respiratory compromise, the first pamidronate infusion cycle may be associated with an acute deterioration of respiratory function. The etiology is unclear but may involve cytokine release and/or hemodynamic compromise from fluid administration during the first infusion cycle. Close monitoring throughout the first treatment cycle is of paramount importance. (C) 2004 Elsevier Inc. All rights reserved.